EULARRheumatology2022Updated 2022

EULAR Recommendations for the Management of Rheumatoid Arthritis 2022

Published by European League Against Rheumatism · 58 pages · Class I–II

5Overarching Principles

11Recommendations

YesJAKi Safety Update

Summary

Free preview

Updated EULAR RA recommendations reinforce treat-to-target with DAS28 remission as primary goal. JAK inhibitors now carry updated cardiovascular and malignancy safety considerations. csDMARD monotherapy (MTX) remains first-line; biologics and JAKi added when targets not met after 3–6 months.

Rheumatoid ArthritisMTXbDMARDJAK inhibitorsTreat-to-targetDAS28

Key Recommendations

Evidence Grading & Drug Doses

What's New vs Previous Version

Implementation & Clinical Pearls

Full guideline access requires an account

Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.

Full guideline text with all recommendations

Evidence grades (Class I/II/III, Level A/B/C)

AI-generated summary and clinical pearls

Auto-logged as CPD/CME activity

Create Free Account — Instant Access Sign In

Free plan includes 10 guideline reads per day · No credit card required

Loading your page…